Literature DB >> 7529452

Bone pain and radionuclide therapy.

P Vande Streek, R Carretta, F L Weiland.   

Abstract

The Council on Scientific Affairs of the California Medical Association presents the following epitomes of progress in nuclear medicine. Each item, in the judgment of a panel of knowledgeable physicians, has recently become reasonably firmly established, both as to scientific fact and clinical importance. The items are presented in simple epitome, and an authoritative reference, both to the item itself and to the subject as a whole, is generally given for those who may be unfamiliar with a particular item. The purpose is to assist busy practitioners, students, researchers, and scholars to stay abreast of progress in medicine, whether in their own field of special interest or another. The epitomes included here were selected by the Advisory Panel to the Section on Nuclear Medicine of the California Medical Association, and the summaries were prepared under the direction of Dr Lyons and the panel.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529452      PMCID: PMC1022622     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  3 in total

1.  Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.

Authors:  J J Bolger; D P Dearnaley; D Kirk; V J Lewington; M D Mason; P M Quilty; N S Reed; J M Russell; J Yardley
Journal:  Semin Oncol       Date:  1993-06       Impact factor: 4.929

2.  Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.

Authors:  A T Porter; A J McEwan
Journal:  Semin Oncol       Date:  1993-06       Impact factor: 4.929

3.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

Authors:  A T Porter; A J McEwan; J E Powe; R Reid; D G McGowan; H Lukka; J R Sathyanarayana; V N Yakemchuk; G M Thomas; L E Erlich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-02       Impact factor: 7.038

  3 in total
  1 in total

Review 1.  Therapeutic radionuclides in nuclear medicine: current and future prospects.

Authors:  Chai-Hong Yeong; Mu-hua Cheng; Kwan-Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.